Alan Alda says the first Parkinson’s symptom that he experienced ‘was not that well-known’ at the time, adding that he had ...

The protein alpha-synuclein is abundant in healthy brains and plays an important role in enabling communication between nerve ...

Alan Alda Opens Up About Parkinson's Diagnosis: I Can't Wish It Away ...

Alan Alda opens up about Parkinson’s disease in a new interview, sharing, ‘It’s not who I am.’ ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...

A nationwide Finnish cohort study found that people with Parkinson's disease receive anti-osteoporosis medications at rates ...

This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

Researchers at King Abdullah University of Science and Technology (KAUST) in collaboration with the University of Oxford have ...